Boston Scientific
BSX
$50.46
+2.33%
Boston Scientific Corp. is a global medical device company specializing in less invasive technologies across interventional cardiology, peripheral interventions, cardiac rhythm management, endoscopy, urology, and neuromodulation. As a top-tier player in the medical devices industry, it competes with the likes of Medtronic and Abbott, leveraging a diversified portfolio and a strong pipeline of innovative products. The current investor narrative centers on the company's strategic $1.5 billion investment in MiRus to enter the high-growth TAVR market, which has garnered Wall Street attention, while the stock has faced significant volatility due to underwhelming trial results and broader market sell-offs, creating a debate about its long-term growth prospects versus near-term headwinds.…
BSX
Boston Scientific
$50.46
Related headlines
BSX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Boston Scientific's 12-month outlook, with a consensus price target around $62.69 and implied upside of +24.2% versus the current price.
Average Target
$62.69
0 analysts
Implied Upside
+24.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$44 - $94
Analyst target range
The target price range spans from a low of $44.00 to a high of $94.00, reflecting a wide dispersion of expectations. The high target of $94.00 assumes a successful execution of the TAVR market entry and a return to historical growth rates, while the low target of $44.00 prices in potential setbacks in clinical trials or competitive pressures. The wide spread between the low and high targets indicates elevated uncertainty, but the recent string of 'Buy' ratings and the average target's significant upside suggest that analysts view the current price as an attractive entry point.
BSX Technical Analysis
Boston Scientific's stock is in a pronounced downtrend, with a 1-year price change of -52.11% and a 6-month change of -35.36%. The current price of $49.30 sits at approximately 10.6% above its 52-week low of $42.20 and 55% below its 52-week high of $109.50, indicating that the stock is trading near the lower end of its range. This positioning suggests that the market has priced in significant negative sentiment, potentially offering a value opportunity if fundamentals stabilize, but also reflecting a falling knife risk if the downtrend persists.
Beta
0.57
0.57x market volatility
Max Drawdown
-60.6%
Largest decline past year
52-Week Range
$42-$110
Price range past year
Annual Return
-51.1%
Cumulative gain past year
| Period | BSX Return | S&P 500 |
|---|---|---|
| 1m | +12.7% | +2.4% |
| 3m | -6.7% | +4.7% |
| 6m | -31.3% | +11.7% |
| 1y | -51.1% | +21.3% |
| ytd | -46.7% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BSX Fundamental Analysis
Boston Scientific's revenue growth remains robust, with the most recent quarter (Q1 2026) reporting revenue of $5.203 billion, a 11.58% YoY increase from $4.663 billion in Q1 2025. This growth is accelerating, as the prior four quarters showed revenue of $5.286 billion (Q4 2025), $5.065 billion (Q3 2025), $5.061 billion (Q2 2025), and $4.663 billion (Q1 2025), indicating a consistent upward trajectory. The Cardiovascular segment, which generated $3.493 billion in the latest quarter, is the primary growth driver, while MedSurg contributed $1.814 billion, reflecting the company's diversified portfolio.
Quarterly Revenue
$5.2B
2026-03
Revenue YoY Growth
+11.6%
YoY Comparison
Gross Margin
69.4%
Latest Quarter
Free Cash Flow
$3.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BSX Overvalued?
Given that Boston Scientific has positive net income, the PE ratio is the most appropriate valuation metric. The trailing PE stands at 48.65x, while the forward PE is 14.34x, a significant discount that implies the market expects substantial earnings growth in the coming year. This gap suggests that the market is pricing in a strong recovery in profitability, which aligns with the company's recent margin expansion and strategic investments.
PE
48.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 17x~88x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.7x
Enterprise Value Multiple